News
PPBT
4.110
-4.20%
-0.180
Purple Biotech CEO Gil Efron files initial beneficial ownership statement
Reuters · 5d ago
Purple Biotech Head of Clinical, Reg Affairs Schickler files initial beneficial ownership statement
Reuters · 6d ago
Weekly Report: what happened at PPBT last week (0323-0327)?
Weekly Report · 03/30 09:50
Purple Biotech files initial beneficial ownership statement; Director Shai Lankry reports 3.55 million ordinary shares
Reuters · 03/27 16:10
Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
TipRanks · 03/25 12:32
Purple Biotech announces collaboration with Converge Bio
TipRanks · 03/25 12:17
Purple Biotech partners with Converge Bio; collaboration expands AI-driven tri-specific antibody development platform
Reuters · 03/25 12:04
Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform
Benzinga · 03/25 12:02
PURPLE BIOTECH ANNOUNCES AI COLLABORATION WITH CONVERGE BIO TO ACCELERATE DEVELOPMENT OF ITS NEXT-GENERATION TRI-SPECIFIC ANTIBODY PLATFORM
Reuters · 03/25 12:00
Weekly Report: what happened at PPBT last week (0316-0320)?
Weekly Report · 03/23 09:48
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
TipRanks · 03/20 13:30
Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
TipRanks · 03/20 06:01
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
TipRanks · 03/19 12:42
Purple Biotech Director Robert E. Gagnon Files Initial Beneficial Ownership Statement
Reuters · 03/18 22:07
Purple Biotech regains Nasdaq compliance with $1 minimum bid price rule
Reuters · 03/17 11:04
PURPLE BIOTECH REGAINS COMPLIANCE WITH NASDAQ
Reuters · 03/17 11:00
Weekly Report: what happened at PPBT last week (0309-0313)?
Weekly Report · 03/16 09:47
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), OnKure Therapeutics (OKUR) and Purple Biotech (PPBT)
TipRanks · 03/16 07:40
Purple Biotech Non-GAAP EPS of $19.85
Seeking Alpha · 03/13 19:21
Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright
TipRanks · 03/13 17:47
More
Webull provides a variety of real-time PPBT stock news. You can receive the latest news about Purple Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.